<DOC>
	<DOCNO>NCT02758132</DOCNO>
	<brief_summary>This correlative study characterize serum metabolite associate bone deposition , growth turnover patient newly diagnose metastatic CRPC currently receive bone target agent .</brief_summary>
	<brief_title>Denosumab Plus Enzalutamide , Abiraterone Prednisone Compared Denosumab Plus Enzalutamide Alone Men With Castrate Resistant Prostate Cancer ( CRPC ) With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Histologic proof adenocarcinoma prostate clinical evidence metastatic disease bone . Castrate resistant progression prostate carcinoma , show : Serum testosterone level &lt; 50 ng/dL prior bilateral orchiectomy . Treatment maintain castrate level testosterone continue , Either symptomatic progression , , patient asymptomatic rise serum PSA two occasion least 1 week apart , minimum pretreatment serum PSA 5 ng/dL . Patients nodal disease eligible . Bidimensionally measurable disease within bone . Life expectancy least 12 week . ECOG Performance status &lt; 2 Adequate : Bone marrow function ; absolute neutrophil count &gt; 1,500 mm3 , platelet count &gt; 100,000 mm3 hemoglobin &gt; 9.0 gm/dl . Hepatic function ; SGOT/SGPT conjugate bilirubin less twice upper limit normal . Renal function ; serum creatinine ≤ 2 mg/dL ( , creatinine &gt; 2 mg/dL , creatinine clearance least 35 ml/min ( measure estimate Cockroft formula : CLcr = [ ( 140age ) x wt ( kg ) ] / [ 72 x serum creatinine ( mg/dL ) ] . No evidence coagulopathy indicate PT &lt; 1.5X upper limit normal . Serum calcium ( correct ) 8 to11.5 mg/dL ( 2 2.9 mmol/L ) Patients must sign informed consent indicate aware investigational nature study . Patients variant histology ( e.g. , ductal small cell carcinoma ) . Patients visceral disease ineligible . Patients prior SipuleucelT , docetaxel , cabazitaxel , abiraterone enzalutamide single agent , combination therapy . Concurrent cancer chemotherapy , radiotherapy surgery . Concurrent serious infection . Life threaten illness ( e.g. , congestive heart failure , uncontrolled angina myocardial infarction prior six month ) . Hypertension uncontrolled medication . Patients know require invasive dental procedure . No know suspect brain metastasis ( NOTE : patient treat epidural disease allow ) Administration investigational drug within 28 day prior receipt denosumab . Age ≤ 18 year age</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Castrate-resistant prostate cancer bone metastasis</keyword>
</DOC>